

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

MTA Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

| |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
| No |
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
| n/a |
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
| n/a |
| 4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made? |
| No |

Approved by Associate Director (name): Henry Edwards

Date: September 2021